Skip to main content
. 2004 Oct 25;101(50):17456–17461. doi: 10.1073/pnas.0407061101

Fig. 5.

Fig. 5.

In the cellular context of Pro/Pre B cells, NaPP1 is quantitatively and qualitatively as effective as imatinib mesylate in suppressing BCR-ABL-induced cell expansion. Generation of B-ALL was as described in Materials and Methods. (A) Flow cytometry analysis of EGFP, BP-1, and B220 expression was as described (26–28). (B) NaPP1 (2 μM), imatinib mesylate (2 μM), and ACK45 (10 μg/ml) inhibitor concentrations were added every 24 h in combinations shown to BCR-ABL T315A-expressing Pro/Pre B cells, and viable cell counts as measured by trypan blue exclusion were obtained 48 h after inhibitor addition. BCR-ABL T315A-expressing Pro/Pre B cells were maintained as described (28). (C) Inhibitor concentrations as shown in B were added, and levels of annexin V staining were measured 48 h after inhibitor addition as described in Materials and Methods and ref. 26. (D) Inhibitor concentrations as described in B and DNA content for cell cycle analysis measured as described in Materials and Methods. (E) Concentrations of NaPP1 (2 μM) and imatinib mesylate (2 μM) were added to BCR-ABL T315A-expressing Pro/Pre B cells, and levels of noted proteins were measured 6 h after inhibitor addition as described in Materials and Methods. Two separate experiments were conducted in duplicate with similar results.